<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03707769</url>
  </required_header>
  <id_info>
    <org_study_id>14/0845</org_study_id>
    <nct_id>NCT03707769</nct_id>
  </id_info>
  <brief_title>TIPS Microspheres for Perianal Fistula</brief_title>
  <official_title>First-in-human Open Label Feasibility Study to Assess the Safety of TIPS Microspheres in Perianal Fistulas</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University College, London</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University College London Hospitals</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University College, London</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Phase of Investigation: First-in-human feasibility study&#xD;
&#xD;
      Objectives: Primary objective: Demonstration that TIPS microspheres do not compromise the&#xD;
      clinical condition or safety of the patient.&#xD;
&#xD;
      Secondary objective: To demonstrate that TIPS microspheres facilitate natural healing in the&#xD;
      context of perianal fistula.&#xD;
&#xD;
      Type of Investigation: First-in-human single site, open label, feasibility study to assess&#xD;
      the safety of TIPS microspheres in perianal fistulas and indicative functionality.&#xD;
&#xD;
      Investigation design and methods: First-in-human single delivery of a bioabsorbable device to&#xD;
      treat perianal fistula. A standard of care internal flap procedure performed to close the&#xD;
      internal fistula opening and up to 300 mg of TIPS microspheres will be inserted into each&#xD;
      perianal fistula. Participants will be assessed for healing, inflammation, abscess, sepsis,&#xD;
      pain and continence by clinical assessments, blood tests, MRI and questionnaires.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      TIPS microspheres are manufactured from GMP grade poly(lactide-co-glycolide) (PLGA) under&#xD;
      Good Laboratory Practice (GLP) conditions.&#xD;
&#xD;
      Microspheres will be delivered into the fistula tract using the following procedure:&#xD;
&#xD;
      i) Tract identification with special emphasis on locating the internal and external openings&#xD;
      using a fistula probe.&#xD;
&#xD;
      ii) Curettage to remove epithelium lining the tract and cleaning by irrigation with hydrogen&#xD;
      peroxide and saline.&#xD;
&#xD;
      iii) Closure of the internal opening by means of a rectoanal advancement flap. iv) Following&#xD;
      device kit instructions, prepare a paste of TIPS microspheres with GranuGel.&#xD;
&#xD;
      v) Introduction of TIPS microsphere paste by back-filling. vi) Retention of the microsphere&#xD;
      paste using Comfeel adhesive hydrocolloid dressing designed to remain in place for 1 - 14&#xD;
      days.&#xD;
&#xD;
      Each subject will receive a single administration of up to 300 mg of TIPS microspheres&#xD;
      implanted into the fistula tract.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 15, 2017</start_date>
  <completion_date type="Anticipated">April 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">April 30, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]</measure>
    <time_frame>Within 9 months of device implantation</time_frame>
    <description>Safety as defined by morbidity, measured by occurrence of adverse events / reactions, in particular: perianal sepsis, perianal abscess, or reoperation due to sepsis</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical evidence of fistula healing</measure>
    <time_frame>9 months after device implantation</time_frame>
    <description>Efficacy through facilitation of natural healing as determined by: clinical evidence of fistula healing; MRI evidence of fistula healing; improvement of quality of life assessment Improvement of pain score assessment</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">15</enrollment>
  <condition>Perianal Fistula</condition>
  <arm_group>
    <arm_group_label>Fistula treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment of fistula with TIPS microspheres</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>TIPS microspheres</intervention_name>
    <description>TIPS microspheres manufactured from GMP grade poly(lactide-co-glycolide) (PLGA) prepared as a paste with GranuGel.</description>
    <arm_group_label>Fistula treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age 18 years and above&#xD;
&#xD;
          -  Cryptoglandular perianal fistula&#xD;
&#xD;
          -  High and low simple trans-sphincteric fistula&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Secondary fistula, including Crohn's disease, carcinoma, radiotherapy, tuberculosis&#xD;
&#xD;
          -  Evidence of branching fistula anatomy or cavity on MRI&#xD;
&#xD;
          -  Inter-sphincteric fistula&#xD;
&#xD;
          -  Low trans-phincterictrans-sphincteric fistula amenable to simple fistulotomy&#xD;
&#xD;
          -  Immunosuppressed patients&#xD;
&#xD;
          -  Participants less than 18 years of age&#xD;
&#xD;
          -  Unable to consent&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Richard Day, PhD</last_name>
    <phone>+442031082183</phone>
    <email>r.m.day@ucl.ac.uk</email>
  </overall_contact>
  <location>
    <facility>
      <name>University College London Hospitals</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nimrita Verma</last_name>
    </contact>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>October 12, 2018</study_first_submitted>
  <study_first_submitted_qc>October 12, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 16, 2018</study_first_posted>
  <last_update_submitted>November 10, 2020</last_update_submitted>
  <last_update_submitted_qc>November 10, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 12, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rectal Fistula</mesh_term>
    <mesh_term>Fistula</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

